Development and Evaluation of Sustained Release Carvedilol Microspheres Prepared by Ionotropic Gelation Technique

Cardiovascular disorders require long-term treatment and continuous medication adherence to achieve effective disease management. Carvedilol is an important antihypertensive and cardioprotective drug widely used in the treatment of hypertension and heart failure. However, its therapeutic performance may be affected by poor aqueous solubility, extensive first-pass metabolism, and limited oral bioavailability. These challenges highlight the need for a drug delivery system capable of providing prolonged drug release and maintaining therapeutic drug levels for an extended period. The present study focused on the development of Carvedilol-loaded microspheres using the ionotropic gelation technique. Sodium alginate was selected as the polymeric carrier because of its biocompatibility, biodegradability, and gel-forming ability in the presence of calcium ions. Microspheres were prepared by ionic cross-linking and subsequently evaluated for their physicochemical and release characteristics. Various parameters, including percentage yield, particle size, drug entrapment efficiency, flow properties, and in vitro drug release, were assessed to determine the suitability of the developed formulations. The prepared microspheres demonstrated satisfactory formulation characteristics with effective drug incorporation and controlled-release behavior. Drug release was prolonged due to the formation of a cross-linked polymeric matrix, indicating the potential of the system to sustain drug delivery over an extended period. The optimized formulation exhibited desirable pharmaceutical properties and a release profile suitable for sustained therapeutic action. The study demonstrates that ionotropically gelled Carvedilol microspheres can be successfully developed as a sustained-release delivery system. Such a formulation may contribute to improved therapeutic effectiveness, reduced dosing frequency, and enhanced patient convenience during long-term cardiovascular therapy.